-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Pentoxifylline
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/6493-05-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 6493-05-6 |
| Description | Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. It improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. It also reduces AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines. |
Product Information
| Synonyms | Trental; PTX; Oxpentifylline |
| IUPAC Name | 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione |
| Molecular Weight | 278.31 |
| Molecular Formula | C13H18N4O3 |
| Canonical SMILES | CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C |
| InChI | InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 |
| InChIKey | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
| Boiling Point | 531.3±56.0 °C at 760 mmHg |
| Melting Point | 98-100°C |
| Flash Point | 275.1±31.8 °C |
| Purity | >98% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to off-white (Solid) |
| Application | Free Radical Scavengers |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 426 |
| Exact Mass | 278.13789045 |
| Index Of Refraction | 1.621 |
| In Vitro | Pentoxifylline (0.1-50 mM; 24-48 hours) inhibits cell proliferation in a dose-dependent manner. Pentoxifylline (0.5 mM; 12-36 hours) increases Apoptosis and decreases Autophagy levels in MDA-MB-231 cells. Pentoxifylline (0.5 mM; 12-36 hours) induces Autophagy in MDA-MB-231 cells. Pentoxifylline (0.5 mM; 24-48 hours) blocks cell cycle at the G0/G1 phase. Pentoxifylline results in high LC3-II/LC3-ratio. |
| In Vivo | Pentoxifylline (200 mg/kg; i.p.) has a protective effect on rats with transient global ischemia and reduces cognitive impairment. |
| PSA | 78.89000 |
| Target | Phosphodiesterase (PDE); Autophagy; HIV |
| Vapor Pressure | 0.0±1.4 mmHg at 25°C |
| XLogP3-AA | 0.3 |
